James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects
2017 ASTRO Annual Meeting
James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4).
Shrinivas Rathod, MD, of the University of Manitoba, discusses phase III study results on optimization of treatment of advanced non–small cell lung cancer using radiation therapy and chemotherapy (Abstract 223).
Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response assessment (Presentation 298).
William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, and surgery in men with high-risk, nonmetastatic adenocarcinoma of the prostate (Abstract 15).
Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer (Abstract PL01).
Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).